Statement of Changes in Beneficial Ownership (4)
21 April 2020 - 9:27AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
LAROSA JOSEPH J |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP General Counsel and Secret |
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/16/2020 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 4/16/2020 | | M(1) | | 5000 | A | $59.2 | 19438 | D | |
Common Stock | 4/16/2020 | | F(1) | | 2733 | D | $529.79 | 16705 | D | |
Common Stock | 4/17/2020 | | S(1) | | 95 | D | $541.94 | 16610 | D | |
Common Stock | 4/17/2020 | | S(1) | | 5 | D | $542.31 | 16605 | D | |
Common Stock | 4/17/2020 | | S(1) | | 100 | D | $547.0 | 16505 | D | |
Common Stock | 4/17/2020 | | S(1) | | 99 | D | $548.27 | 16406 | D | |
Common Stock | 4/17/2020 | | S(1) | | 100 | D | $549.24 | 16306 | D | |
Common Stock | 4/17/2020 | | S(1) | | 6 | D | $550.0 | 16300 | D | |
Common Stock | 4/17/2020 | | S(1) | | 104 | D | $552.85 | 16196 | D | |
Common Stock | 4/17/2020 | | S(1) | | 114 | D | $555.1 | 16082 | D | |
Common Stock | 4/17/2020 | | S(1) | | 198 | D | $556.51 (2) | 15884 | D | |
Common Stock | 4/17/2020 | | S(1) | | 93 | D | $557.4 | 15791 | D | |
Common Stock | 4/17/2020 | | S(1) | | 293 | D | $558.55 (3) | 15498 | D | |
Common Stock | 4/17/2020 | | S(1) | | 285 | D | $559.79 (4) | 15213 | D | |
Common Stock | 4/17/2020 | | S(1) | | 163 | D | $560.38 (5) | 15050 | D | |
Common Stock | 4/17/2020 | | S(1) | | 63 | D | $561.76 | 14987 | D | |
Common Stock | 4/17/2020 | | S(1) | | 191 | D | $562.56 (6) | 14796 | D | |
Common Stock | 4/17/2020 | | S(1) | | 171 | D | $563.39 (7) | 14625 | D | |
Common Stock | 4/17/2020 | | S(1) | | 93 | D | $564.19 | 14532 | D | |
Common Stock | 4/17/2020 | | S(1) | | 94 | D | $565.92 (8) | 14438 | D | |
Common Stock | 4/17/2020 | | M(1) | | 6622 | A | $59.2 | 21060 | D | |
Common Stock | 4/17/2020 | | F(1) | | 3602 | D | $555.82 | 17458 | D | |
Common Stock | 4/17/2020 | | M(1) | | 5000 | A | $59.2 | 22458 | D | |
Common Stock | 4/17/2020 | | F(1) | | 2720 | D | $555.82 | 19738 | D | |
Common Stock | 4/20/2020 | | S(1) | | 51 | D | $561.57 | 19687 | D | |
Common Stock | 4/20/2020 | | S(1) | | 21 | D | $562.71 | 19666 | D | |
Common Stock | 4/20/2020 | | S(1) | | 416 | D | $563.58 (9) | 19250 | D | |
Common Stock | 4/20/2020 | | S(1) | | 377 | D | $564.74 (10) | 18873 | D | |
Common Stock | 4/20/2020 | | S(1) | | 1468 | D | $565.6 (11) | 17405 | D | |
Common Stock | 4/20/2020 | | S(1) | | 1189 | D | $566.44 (12) | 16216 (13) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 198 shares of Company stock on April 17, 2020 at prices ranging from $556.43 to $556.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. |
(3) | Represents volume-weighted average price of sales of 293 shares of Company stock on April 17, 2020 at prices ranging from $558.42 to $558.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. |
(4) | Represents volume-weighted average price of sales of 285 shares of Company stock on April 17, 2020 at prices ranging from $559.47 to $559.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. |
(5) | Represents volume-weighted average price of sales of 163 shares of Company stock on April 17, 2020 at prices ranging from $560.27 to $560.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. |
(6) | Represents volume-weighted average price of sales of 191 shares of Company stock on April 17, 2020 at prices ranging from $562.31 to $562.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. |
(7) | Represents volume-weighted average price of sales of 171 shares of Company stock on April 17, 2020 at prices ranging from $563.33 to $563.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. |
(8) | Represents volume-weighted average price of sales of 94 shares of Company stock on April 17, 2020 at prices ranging from $565.77 to $565.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. |
(9) | Represents volume-weighted average price of sales of 416 shares of Company stock on April 20, 2020 at prices ranging from $563.35 to $563.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. |
(10) | Represents volume-weighted average price of sales of 377 shares of Company stock on April 20, 2020 at prices ranging from $564.03 to $564.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. |
(11) | Represents volume-weighted average price of sales of 1,468 shares of Company stock on April 20, 2020 at prices ranging from $565.03 to $565.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. |
(12) | Represents volume-weighted average price of sales of 1,189 shares of Company stock on April 20, 2020 at prices ranging from $566.00 to $566.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price. |
(13) | Form one of two |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
LAROSA JOSEPH J 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 |
|
| EVP General Counsel and Secret |
|
Signatures
|
/s/**Joseph J. LaRosa | | 4/20/2020 |
**Signature of Reporting Person | Date |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024